Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 13,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer (Locally Advanced or Metastatic), Lymphoma, Colorectal Cancer
Interventions: ASSIST phone application; Other
Lead sponsor: Patrick C. Johnson, MD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Cholecalciferol; Drug
Lead sponsor: Katherine D. Crew; Other
Eligibility: 21 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Laxity
Interventions: Ulthera System Treatment; Device
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 25 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Melanoma (Skin)
Interventions: boronophenylalanine-fructose complex; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling; Radiation · Drug · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, BRCA Mutation
Interventions: Tranexamic acid, Normal saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Quality of Life, Communication
Interventions: Together After Cancer; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Tampa, Florida

Conditions: HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
Interventions: IAM1363; Drug
Lead sponsor: Iambic Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 29
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 23 more

Conditions: Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer, Other Female Genital Malignant Neoplasms
Interventions: INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 2,748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Birmingham, Alabama • Los Angeles, California • Oklahoma City, Oklahoma

Conditions: Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
Interventions: Bempegaldesleukin, Nivolumab; Biological
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 62
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions: NAET Procedures; Procedure
Lead sponsor: Nambudripad's Allergy Research Foundation; Other
Eligibility: 2 Years to 78 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Buena Park, California

Conditions: Atopic Dermatitis
Interventions: GIA632, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Fremont, California • Rockville, Maryland • Hoboken, New Jersey

Conditions: Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Interventions: Neratinib Oral Tablet, Ruxolitinib Oral Tablet; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: ipilimumab, cyclophosphamide, biopsy, aldesleukin, immunohistochemistry staining method, polymerase chain reaction, immunoenzyme technique, therapeutic cytotoxic T lymphocytes; Biological · Drug · Procedure + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Early Breast Cancer
Interventions: Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 79
States / cities: Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 69 more

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 121
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more

Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
Interventions: Rituximab, Azathioprine; Biological · Drug
Lead sponsor: Cambridge University Hospitals NHS Foundation Trust; Other
Eligibility: 15 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota + 6 more

Conditions: Severe Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 9
States / cities: Los Angeles, California • Miami, Florida • Meridian, Idaho + 6 more

Conditions: Breast Cancer
Interventions: Ketogenic diet; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Tucatinib, Doxil; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Columbia, Maryland • Bensalem, Pennsylvania • Nashville, Tennessee + 4 more

Conditions: Rosacea
Interventions: Anatabloc Cream, Placebo Cream; Other
Lead sponsor: Rock Creek Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Bradenton, Florida • New Orleans, Louisiana • New York, New York

Conditions: Vascular Ehlers-Danlos Syndrome
Interventions: Heartmath Intervention, Control Group; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-176; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Scottsdale, Arizona • Duarte, California • New Haven, Connecticut + 4 more

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 4,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 914
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more

Search by objective public record fields.

Remote Monitoring and Symptom Management Digital Application

Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer

Feasibility Study: Higher Density Ulthera® System Treatment With Vectoring for Treatment of the Face and Neck

Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage

Together After Cancer

A Phase 1/1b Study of IAM1363 in HER2 Cancers

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Rituximab Vasculitis Maintenance Study

A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

Impact of Ketogenic Diet on Tumor Microenvironment in Patients With Breast Cancer

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea

Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer